Under separate licensing agreements between the Johns Hopkins University and Guilford Pharmaceuticals, Inc. and the Johns Hopkins University and Angiotech Pharmaceuticals, Inc., Dr. Brem is entitled to a share of royalty received by the University on sales of products described in this work. Dr. Brem owns Guilford Pharmaceuticals, Inc. stock, which is subject to certain restrictions under University policy. Dr. Brem also is a paid consultant to Guilford Pharmaceuticals, Inc. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
Was this article helpful?